73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks

BACKGROUND: Lenacapavir (LEN) is a first-in-class HIV-1 capsid (CA) inhibitor in clinical development for treatment and prevention of HIV-1 infection. CALIBRATE is an ongoing, phase 2 clinical study evaluating subcutaneous (SC) or oral LEN, in combination with other antiretrovirals, in treatment-naï...

Descripción completa

Detalles Bibliográficos
Autores principales: VanderVeen, Laurie, Margot, Nicolas, Naik, Vidula, Chang, Silvia, Martin, Ross, Dvory-Sobol, Hadas, Rhee, Martin, Callebaut, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643997/
http://dx.doi.org/10.1093/ofid/ofab466.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643997/
http://dx.doi.org/10.1093/ofid/ofab466.073

Ejemplares similares